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Discussion results: We found that among patients HCV infection was found in 50 cases 
(66.66%) of them - 4 suffered from acute viral hepatitis C (5.33%) and 46 - with chronic hepatitis C 
(61.33%). Among patients with ALL and HCV infection there was a division of the level of 
transaminases in the blood: 3 patients - the level of ALT and AST was in the normal range (6%) 12 -
had increased level of ALT and AST in 2 times ( 24%), 18 - in 3-5 times (36%), 11 - in 5-9 times (22%) 
and 6 - in 10 and more times (signs of toxic hepatitis) (12%). According to the literature (V. Berezenko 
“Clinical and paraclinical aspects of chronic viral hepatitis C in children”//Perynatology and pediatrics 
2(62), 2015) in HCV patients without comorbidity was observed following distribution: 28 patients 
(43.75%) - normal levels of transaminases, 20 (31.25%) - increased in 2 times, 16 (25 %) - in 3-5 times, 
0 – increased in 5 - 9 times, 0 – in more than 10 times. In patients with ALL and HCV statistically 
significant (p <0,05) that level of transaminases was higher than in patients without ALL, indicating a 
greater severity of cytolytic syndrome in children with ALL and HCV. In patients who were treated with 
chemotherapy, but not infected with HCV there was not observed expressed cytolytic syndrome.
Conclusions: In patients which suffer from ALL and HCV was observed more expressed 
cytolytic syndrome (increased ALT and AST) than in patients with HCV without comorbidity. In 
patients with ALL without concomitant HCV was not observed cytolytic syndrome during PCT 
treatment. Thus, the HCV infection causes more expressed liver injury in the presence of comorbidity, 
in this case, ALL, and increases the risk of toxic hepatitis in patients with ALL during PCT treatment.
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Introduction: The problem of chronic hepatitis C (CHC) is one of the most pressing problems 
of modern health care. Each year between 3 and 4 million people are getting infected. Due to the rapidly 
spreading of infection, lack of specific vaccination, a high frequency of chronic infection, frequent 
adverse effects of the disease, expensive treatment of chronic hepatitis C and its complications - the 
problem is not only medical but also social and economic. One of the modern standards of treatment of 
chronic hepatitis C in Ukraine is using a combination of antiviral therapy (AVT) (Pegylated interferon 
and Ribavirin). Approximately 60% of patients achieve sustained virological response. Due to the 
possible risk of relapse after complete treatment, and side effects of antiviral drugs, the importance of 
determining predictors efficiency of AVT. In 2009 was published a first report on the existence of a 
specific IL28B-gene polymorphisms, which nucleotide sequence was different depending on the 
response to combined antiviral therapy.
Materials and Methods: We have analyzed 40 patients with chronic hepatitis C infected with 
genotype 1 virus. Among observed were more men - 25 (62.5%) patients. The average age of the patients 
was (38,46 ± 2,4) years. All patients were on in/outpatient treatment of 
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Vinnytsia and were treated with combinated antiviral therapy (Ribavirin+PegIFN 2a) during 2014-
2015 years. All patients with chronic hepatitis C were conducted molecular genetic analysis to determine 
IL28B-gene polymorphism using PCR. 
Discussion results: According to the data obtained among patients with chronic hepatitis C more 
than half of the patients (21 patients - 52.5%) were carriers of C/T genotype. Genotype C/C of IL28V-
gene occurred in 32.5% (13 patients). T / T genotype was observed only in 15% (6 patients). Analysis 
of the effectiveness of combination antiviral therapy in patients with chronic hepatitis C genotype 1 of 
the virus has set it differs depending on the genotype of the gene IL28V. Thus,  was found that stable 
virological response (SVR) was observed mainly in patients with C/C genotype (at 75.33%) and 
occurred in 1.9 and 2.9 times higher in comparison with patients who were carriers C/T (39.9%) and T/T 
(25.9%) genotypes gene IL28V.
Conclusions: The presence of C/C genotype IL28V gene may be a prognostic predictors of 
efficiency dual combination antiviral therapy in patients with chronic hepatitis C genotype 1 of the virus 
(SVR was recorded at 75.3%).
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Introduction. Atrial fibrilation is the most common cardiac arhytmia and is Associated with a 
substantial risk of stroke and mortality.The prevalence of atrial fibrillation is related to age and is 
projected to rise exponentially as the population ages and the prevalence of cardiovascular risk factors 
increases. The risk of ischemic stroke is significantly increased at atrial fibrillation patients, and there is 
evidence of increased risk of stroke Associated with advancing age. The objective of the study is the 
determination of thromboembolic risk at the patients with non-valvular fibrillation with the 
CHA2DS2VASc.
Materials and methodes. This study was conducted on 110 patients (aged 47 and 83 years old) 
with non-valvular atrial fibrillation, hospitalized in MCH,,Holy Trinity’’ during october 2014 - march 
2016. The study was made on 65 females(59,09%) and 45 males(40,91%).The factors that could 
influence the thromboembolic risk were analyzed. Were utilized the next tests: CHA2DS2VASc score 
and HAS-BLED score. Laboratory analysis: Total Cholesterol; HDL- cholesterol; Triglycerides; 
Glycemie; Body mass index. 
Results. Pacients with age less than 65 years: 11(10%-males:4,5% and females:5,5%); 65-75
years: 70(63,63%- males: 28,2% and females 35,5%); older than 75 years: 29(26,36% -males:8,18% and 
females:18,18%). At the patients with the following risk factors were identified: the low thromboembolic 
risk-0%; moderate – 2,73%; high – 97,2%. The predominant risk factors: arterial hypertension-
93,63%(103); diabetes mellitus-24,6% (27); vascular disease( MI, PAD)-15,45% (17); stroke/TiA or 
thromboembolism-10,91% (12).
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